# Development and preliminary testing of Health Equity Across the AI Lifecycle (HEAAL): A framework for healthcare delivery organizations to mitigate the risk of AI solutions worsening health inequities

Jee Young Kim[1], Alifia Hasan[1], Kate Kellogg[2], William Ratliff[1], Sara Murray[3], Harini Suresh[4], Alexandra Valladares[5], Keo Shaw[6], Danny Tobey[7], David E Vidal[8], Mark A Lifson[8], Manesh Patel[9], Inioluwa Deborah Raji[10], Michael Gao[1], William Knechtle[1], Linda Tang[11], Suresh Balu[1], Mark P Sendak[1]

[1] Duke Institute for Health Innovation, Duke Health, Durham, NC, USA

[2] Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA

[3] Division of Hospital Medicine, University of California San Francisco, San Francisco, CA, USA

[4] Cornell University, New York, NY, USA

[5] Community representative, Durham, NC, USA

[6] FDA Regulatory Group, DLA Piper, San Francisco, CA, USA

[7] AI and Data Analytics, DLA Piper, Dallas, TX, USA

[8] Center for Digital Health, Mayo Clinic, Rochester, MN, USA

[9] Division of Cardiology, Duke Health, Durham, NC, USA

[10] Department of Electrical Engineering and Computer Science, University of California Berkeley, Berkeley, CA, USA

[11] School of Medicine, Johns Hopkins University, Baltimore, MD, USA

* Corresponding author: Jee Young Kim

E-mail: jee.young.kim@duke.edu

# Abstract

The use of data-driven technologies such as Artificial Intelligence (AI) and Machine Learning (ML) is growing in healthcare. However, the proliferation of healthcare AI tools has outpaced regulatory frameworks, accountability measures, and governance standards to ensure safe, effective, and equitable use. To address these gaps and tackle a common challenge faced by healthcare delivery organizations, a case-based workshop was organized and a framework to assess the potential impact of a new AI solution on health equity was developed. The Health Equity Across the AI Lifecycle (HEAAL) is co-designed with extensive engagement of clinical, operational, technical, and regulatory leaders across healthcare delivery organizations and ecosystem partners in the US. It assesses 5 equity assessment domains–accountability, fairness, fitness for purpose, reliability and validity, and transparency–across the span of 8 key decision points in the AI adoption lifecycle. It is a process-oriented framework containing 37 step-by-step procedures for evaluating an existing AI solution and 34 procedures for evaluating a new AI solution in total. Within each procedure, it identifies relevant key stakeholders and data sources used to conduct the procedure. HEAAL guides how healthcare delivery organizations may mitigate the potential risk of AI solutions worsening health inequities. It also informs how much resources and support are required to assess the potential impact of AI solutions on health inequities.

# Introduction

The use of data-driven technologies such as Artificial Intelligence (AI) and Machine Learning (ML) is growing in healthcare. These technologies can be valuable tools for streamlining clinical workflow, aiding clinical decision-making, and improving clinical operations [1-4]. For example, the integration of AI and ML in healthcare helps in the detection and management of sepsis [5], preventing unanticipated intensive care unit transfers [6], and automated calculation of left ventricular ejection fraction [7]. AI and ML can promote earlier detection of diseases, more consistent collection and analysis of medical data, and greater access to care [8].

However, the proliferation of healthcare AI tools has outpaced regulatory frameworks, accountability measures, and governance standards to ensure safe, effective, and equitable use [3, 9, 10]. Past research has shown numerous incidents where healthcare AI technologies perpetuate bias and inequities [11-13]. To address this issue, in 2022 and 2023, government officials from the White House [14], HHS Office of Civil Rights [15], Office of the National Coordinator for Health Information Technology (ONC) [16], and Office of the Attorney General in California [17] took action to protect against healthcare AI worsening inequities. While these regulatory actions describe what harms to avoid, they also leave significant room for interpretation of how healthcare delivery organizations can implement these principles.

Numerous academic papers have surfaced potential causes of bias in AI products, including lack of representation and diversity in model training data [18-20], lack of sufficient historic data to build an accurate model [21], an outlier event with unprecedented data [22], bias captured in specific data measurements [23, 24], bias captured in unstructured text [25, 26], bias embedded within outcome labels used to train models [11, 12], and models learning shortcuts unrelated to disease process to generate diagnostic predictions [27, 28]. Numerous reviews and frameworks have described categories of racial bias in AI products and proposed

steps to address bias [29-33]. But to date, there has yet to be a comprehensive set of procedures across the AI product lifecycle for healthcare delivery organization leaders to adopt internally to mitigate the risk of AI products worsening health inequities.

Our prior work revealed that healthcare delivery leaders find it challenging to identify and objectively measure the potential impact of an AI product on health inequities. We interviewed 89 individuals from 10 US healthcare delivery organizations and ecosystem partners [34]. Even though we interviewed 13 AI ethics and bias experts, we were not able to reach a consensus on the best approaches to assess AI products for potential impacts on health inequities.

## Present research

To address these gaps and tackle a common challenge faced by healthcare delivery organizations, we, the Health AI Partnership (HAIP), organized a case-based workshop [35] and developed a framework to assess the potential impact of a new AI solution on health equity. In the present research, we define health equity as *the attainment of the optimal health for all people regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, and other factors that may affect access to care and health outcomes* [36]. This manuscript describes developing and testing the framework, which we named Health Equity Across the AI Lifecycle (HEAAL). We aim to (1) describe the framework and its development and (2) assess the resources required for healthcare delivery settings to adopt the framework.

# Materials and methods

## Engage and align

HEAAL was co-designed with extensive engagement of clinical, operational, and technical leaders across healthcare delivery organizations and ecosystem partners in the US (Fig 1). Design involved two rounds of divergent and convergent processes with four phases: discover, define, develop, and deliver (Fig 2).

| Participant | | Role | Responsibilities |
|---|---|---|---|
| C | Case study presenters | 3 innovation teams that develop and implement AI solutions in healthcare delivery organizations | Curated a case study, presented it at the workshop and tested out the framework |
| F | Framework developers | Clinician, community representative, computer scientist, project manager, legal expert, and sociotechnical scholar | Created a scaffolding of the framework and contributed to developing its content |
| H | HAIP leaders | Clinicians, computer scientists, lawyers, and a community organizer | Evaluated the framework and provided feedback |
| W | Workshop participants | 77 stakeholders from 10 healthcare delivery organizations and 4 ecosystem partners with clinical, technical, operational, regulatory, and AI ethics expertise | Contributed to developing the content of the framework |
| D | Design researchers | Qualitative research scientist, clinical data scientist, and project manager | Facilitated the co-design process by collecting, iterating, and synthesizing data from all participants |

**Fig 1. A list of participants, roles, and responsibilities in co-designing the HEAAL.**




**Fig 2. Four phases of co-design processes and participants engaged in each phase.**

# Ethics statement

The present research was considered a quality improvement (QI) project that did not involve human subjects research. Thus, it was exempted from IRB review and approval at Duke University Health System. All participants provided verbal consent to participate in the co-design processes and to have anonymized data used in analyses.

# Discover

During the Discover phase, the problem was widely explored by speaking to all participants and documenting their responses.

## Curate case studies

A total of three case studies were curated. A Duke Institute for Health Innovation (DIHI) team developed an initial example case study for a pediatric sepsis prediction algorithm. This

case study was not presented at the workshop but was used to illustrate the case study format to other teams. Teams from NewYork-Presbyterian (NYP) and Parkland Center for Clinical Innovation (PCCI) then curated case studies for postpartum depression and patient segmentation algorithms, respectively, using the structure provided by the DIHI team [37, 38]. The case studies served as real-world examples to facilitate ideation and discussion during the workshop among participants. More information about the workshop is presented in the accompanying Formal Comment [35].

## Surface domains of assessment

Six framework developers–a clinician, a computer scientist, a sociotechnical scholar, a project manager, a legal and regulatory expert, and a community representative–were recruited to create a scaffolding of the framework and contribute to the development of its content. They individually reviewed two case studies and were asked to identify major domains of assessment or concerns that health system leaders should assess when deciding to implement an AI solution into clinical practice safely, effectively, and equitably. For each domain of assessment, they were asked to provide its descriptions and propose how each domain may be assessed and what data may be required.

Design researchers collected responses from framework developers and mapped them on a Miro board, an online whiteboard with infinite canvas, using sticky notes. Then, all framework developers convened to share their responses and categorized sticky notes with similar ideas into clusters on the Miro board. Ultimately, this activity resulted in the creation of eight unique clusters.

### Surface novel insights from the workshop

Seventy-seven people with various domains of expertise from 10 healthcare delivery organizations and 4 ecosystem partners attended the workshop. Clinical, technical, operational, and regulatory stakeholders as well as AI ethics experts shared their perspectives on the workshop topic through different activities as described in the accompanying Formal Comment [35]. Design researchers took notes of the discussions that took place during the workshop.

## Define

During the Define phase, responses collected from all participants were synthesized.

### Synthesize key insights of the workshop

After the workshop, the design researchers compiled their notes and synthesized ideas discussed during the workshop. They mapped key concepts onto the Miro board that framework developers had previously created, organizing ideas from the workshop into the clusters outlined by the framework developers. This activity ensured that novel ideas discussed during the workshop were incorporated into the framework's content.

### Synthesize domains of assessment

Framework developers and design researchers thoroughly reviewed the eight clusters of the sticky notes that contained insights that surfaced from the framework developers and workshop participants and merged clusters with similar ideas. This process reduced the number of clusters from eight to six. Then, design researchers converted the contents on the Miro board to a single Word document. Each cluster of sticky notes was converted to a major domain of assessment in the framework, and each sticky note was converted to a guiding question within an assessment domain. The Word document contained six domains of assessment with

relevant guiding questions listed under each domain of assessment. Fig 3 summarizes how the content of the framework was surfaced and synthesized during the Discover and Define phases.




**Fig 3. Content development and synthesis during the Discover and Define phases.** Colored squares represent sticky notes mapped on the Miro board. They describe domains of assessment identified by framework developers and synthesized key insights from the workshop. Framework developers and design researchers iteratively reviewed and synthesized collected responses to arrive at six domains of assessment with relevant guiding questions.

# Develop

During the Develop phase, prototypes were developed and tested.

## Generate the first prototype

Design researchers shared the Word document with framework developers and asked them to individually provide answers to each guiding question under each domain of assessment. Design researchers then collected responses from framework developers and compiled them in a single document. They arranged the responses in sequential order so that the responses could serve as procedures for assessing a concern described in each guiding question.

All framework developers then reconvened again to review the document together. They resolved conflicts in their responses and provided clarification. After the meeting, design researchers incorporated the feedback and generated the first prototype of the framework. It

contained six assessment domains and relevant sets of actionable procedures under each of the assessment domains.

## Conduct initial usability testing

Data scientists from the DIHI case study team tested the first prototype of the framework. This process was essential to ensure that the framework was pragmatic and usable in practice. The data scientists followed the procedures described in the framework to analyze a pediatric sepsis prediction algorithm. After the analysis, they reported the results of the analysis, shared their experiences using the framework, and suggested areas of improvement.

A major suggestion that the data scientists proposed was to consider restructuring the framework. They found that domains of assessment were not truly independent from one another, meaning that there were some redundant procedures present across different domains. Such redundant procedures not only made them go back and forth between different domains and conduct the same analysis more than once but also prevented them from conducting analyses in sequential order. The data scientists reported that the analysis of some procedures was conducted too late or too early. To address this issue, they recommended listing the procedures of all assessment domains in a sequential order based on the previously developed HAIP 8 key decision points of the AI product life cycle [34].

Another suggestion that the data scientists provided to make the framework more user-friendly was to describe some of the procedures more concretely with actionable guidance. For example, the data scientists requested the framework to explicitly state the required personnel or resources for each procedure. Similarly, additional detail was requested describing the roles and responsibilities of individual decision-makers, by saying “seek approval from _____ stakeholder” rather than “engage _____ stakeholder.”

## Generate the second prototype

Feedback from the data scientists was incorporated into revising the first prototype and generating the second prototype of the framework. The second prototype mapped procedures from the 6 domains of assessment to the HAIP 8 key decision points of the AI product life cycle [34]. At this stage, tags were added to each procedure for relevant stakeholders to be involved, relevant dataset(s) required for analyses, and equity assessment domains.

## Conduct advanced usability testing

A project manager and two data scientists from the DIHI case study team were recruited to test the usability of the second prototype. The team followed the procedures described in the framework to analyze the same pediatric sepsis prediction algorithm. With the updated content and structure of the framework, it was important to examine whether the framework addressed the initial pain points raised from the initial usability testing.

The case study team was satisfied with the updated structure of the framework. They liked how the procedures flowed in a sequential manner from the beginning to the end of the AI lifecycle. The project manager reported that the framework required quite a bit of work yet was reasonable to go through. The project manager found the framework to be particularly helpful in understanding potential gaps in algorithms. The data scientists provided additional feedback on how the assessment could be conducted more efficiently. They suggested rearranging some of the procedures in a different sequential order and requested additional information in some procedures. They also suggested that once an outcome was obtained from conducting its relevant procedure, each procedure should inform the users how to interpret the outcome and clearly state what to do with the outcome.

## Seek general feedback and evaluation

The second prototype was also shared with the framework developers and the HAIP leadership team for review. One major concern was that the framework does not sufficiently describe procedures related to one of the assessment domains, "policy and regulation." HAIP leaders with regulatory expertise cautioned that engaging regulatory stakeholders in some procedures was not sufficient to assess the policy and regulation domain. Fig 4 shows how prototypes were developed during the Develop phase.




**Fig 4. Prototype development during the Develop phase.** Responses to guiding questions were compiled and used to generate prototypes. The first prototype was structured around six domains. Design researchers conducted initial usability testing with a case study team and generated the second prototype. The second prototype was structured around eight key decision points of AI adoption. Design researchers conducted advanced usability testing with the case study team and shared the second prototype with framework developers and HAIP leadership team for feedback and evaluation.

# Deliver

During the Deliver phase, the final prototype was refined and prepared for dissemination. Design researchers compiled feedback from the framework developers, the HAIP leadership team, and the DIHI case study team, revised the prototype, and generated the first version of

the framework. The framework was named Health Equity Across the AI Lifecycle (HEAAL). HEAAL was then shared with two other case study teams. They plan to apply HEAAL in evaluating their postpartum depression and patient segmentation algorithms and publish their findings.

# Results

HEAAL, presented in the supporting information (S1 Table and S2 Document), was established after conducting a series of activities, including curating case studies, surfacing domains of assessment, hosting a workshop, synthesizing insights, developing two prototypes, conducting two rounds of usability testing, and receiving feedback. Over the course of 7 months, clinical, technical, operational, and regulatory stakeholders and AI ethics experts from healthcare delivery organizations and ecosystem partners contributed a great amount of their time and effort to these framework development activities.

## Five domains of assessment

HEAAL addresses 5 health equity assessment domains across the span of 8 key decision points in the AI adoption lifecycle. The 5 equity assessment domains are (1) accountability, (2) fairness, (3) fitness for purpose, (4) reliability and validity, and (5) transparency (Table 1).

**Table 1. Five health equity domains of assessment.**

| Assessment domain | Definition |
|---|---|
| Accountability | Ensures that potential adverse impacts of using the AI solution are overseen by specific stakeholders within healthcare delivery organizations who have clear responsibilities. |
| Fairness | Establishes and evaluates meaningful fairness criteria that can empower the healthcare delivery organization to track progress towards achieving equity objectives and identify problems.<br>Ensures that the solution performs equitably across disadvantaged patient subgroups. |
| Fitness for purpose | Ensures that the proposed solution solves the identified problem for disadvantaged patient subgroups. |
| Reliability and validity | Ensures that the solution achieves pre-specified performance targets across technical, clinical, and process measures. |
| Transparency | Ensures that the processes of model development, implementation, identification of potential risks and harms, and progress towards equity objectives are communicated effectively to end users and members of disadvantaged patient subgroups. |

During and after the workshop, diverse stakeholders expressed the importance of healthcare delivery organizations adapting to the changing regulatory landscape. “Policy and regulation” emerged as a health equity assessment domain from the workshop and framework developers. However, ultimately it was not included in HEAAL, as there was no universal set of procedures that applied to diverse AI use cases across the US. Given the dynamic nature of regulations, the broad coverage of health equity assessment concerns within the framework, and the large number of jurisdiction-specific actions, HAIP leaders confirmed that no single set of procedures could adequately address policy and regulation across diverse AI use cases. For the time being, healthcare delivery organizations need to monitor federal and local regulators, including offices of state Attorney Generals and departments of health. A forum for streamlining and summarizing the evolving landscape may be needed so that healthcare delivery organizations have a go-to place to ensure that they comply with federal and local policy and

regulation. New procedures may need to be added to HEAAL to support healthcare delivery organizations seeking to comply with emerging regulations and policies.

## Structure and procedures

HEAAL is a process-oriented framework that contains a total of 37 step-by-step procedures to systematically assess the potential impact of a new AI solution on health equity. The procedures are tailored to be applicable to evaluate both existing and newly developed solutions and span 8 key decision points of the AI lifecycle. There are 37 procedures involved in evaluating an existing AI solution and 34 procedures for evaluating a new AI solution. Additional procedures are required when evaluating an existing solution to make sure that it aligns with the implementation context. While all procedures should be considered for all AI solutions of interest, some procedures are tested in different decision points or in a different sequential order, depending on whether the solutions already exist or not. To make a distinction between two scenarios, procedures for evaluating an existing AI solution are written in red and black. Procedures for evaluating a new AI solution are written in blue and black (Table 2).

**Table 2. The number of procedures involved in each decision point.**

| Adoption stage | Decision point | Number of procedures for evaluating an existing AI solution | Number of procedures for evaluating a new AI solution |
|---|---|---|---|
| Problem identification and procurement | 1. Identify and prioritize a problem | 2 | 2 |
| | 2. Define AI product scope and intended use | 13 | 5 |
| Development and adaptation | 3. Develop success measures | 2 | 2 |
| | 4. Design AI solution workflow | 5 | 5 |
| | 5. Generate evidence of safety, efficacy, and equity | 6 | 11 |
| Clinical integration | 6. Execute AI solution rollout | 3 | 3 |
| Lifecycle management | 7. Monitor the AI solution | 3 | 3 |
| | 8. Update or decommission the AI solution | 3 | 3 |
| Total | | 37 | 34 |

Each procedure not only contains sub-procedures with detailed steps but also identifies relevant active stakeholders and data sources. Across HEAAL procedures, 8 different types of stakeholders (Table 3) are involved, and 6 different types of data (Table 4) are used for assessing the impact of a new AI solution on health equity. Active stakeholders–other than the product manager and clinical champion–are listed for each procedure. Product managers and clinical champions are assumed to be part of the entire AI solution lifecycle and thus, are not explicitly listed in every procedure. Completing the procedures in each key decision point

involves various stakeholders and data sources and ensures that a selected AI solution is evaluated against five assessment domains for health equity. Table 5 summarizes assessment domains that each key decision point evaluates, active stakeholders, data sources, and key outcomes of each key decision point.

**Table 3. Stakeholders involved in completing the procedures of the framework.**

| Stakeholder type | Definition | Example roles |
|---|---|---|
| Strategic (S) | Stakeholders who develop strategic plans and make decisions that align with organizational interests | Senior leaders (e.g., CEO, CMO), departmental leaders (e.g., medical directors) |
| Operational (O) | Stakeholders who manage workflow and make decisions to integrate | Business unit leaders (e.g., nursing supervisors), diversity, equity, and inclusion (DEI) roles, frontline workers |
| Clinical (C) | Stakeholders who provide clinical care to patients | Frontline clinicians, end-users |
| Technical (T) | Stakeholders who develop the model and its infrastructure | Data scientists, data engineers, UI/UX designers, health IT |
| Regulatory (R) | Stakeholders who review the model from regulatory, compliance, and ethical perspectives | Legal, regulatory affairs, local governance committee, IRB |
| Patient (P) | Stakeholders who receive clinical care and provide insights on their experiences | Patients, patient community representatives |
| Clinical champion | Clinical stakeholders who lead the project and provide clinical expertise in model development | |
| Project manager | Stakeholders who manage the project and communicate with various stakeholders involved in the project | |

**Table 4. Sources of data used to complete the procedures of the framework.**

| Data source | Definition |
|---|---|
| Local healthcare retrospective data | Historical healthcare data that is curated within the primary healthcare delivery organization seeking to adopt an AI product.<br>The local data can be sourced from a variety of systems, including the EHR, radiology PACS system, medical claims, audit logs, electrocardiograms, and high-frequency vital sign monitors.<br>When a model is internally developed, the local healthcare retrospective data set is used for training the model. |
| Local healthcare prospective data | Real-time healthcare data that is curated within the primary healthcare delivery organization seeking to adopt an AI product.<br>The local data can be sourced from a variety of systems, including the EHR, radiology PACS system, medical claims, audit logs, electrocardiograms, and high-frequency vital sign monitors.<br>The local healthcare prospective data set is used for validating a model during a 'silent trial' and for using the model in clinical care. |
| Local non-healthcare data | Non-healthcare data that is curated within a geographic setting where a healthcare delivery organization is based. The local non-healthcare data can be derived from a variety of external sources, including US Census. |
| Training data | Data used for training a model.<br>When the model is externally developed, the training data set contains data from an external source. When the model is internally developed, the training data set is sourced from local healthcare retrospective data. |
| Literature review | Data collected through reviewing previously published scholarly works on a specific topic. |
| Organizational data | Data that describes characteristics of organizations, their internal structures, processes, and behavior as corporate actors in different social and economic contexts.<br>The organizational data includes Key performance Indicators (KPIs) that quantify progress toward strategic and operational goals. |
| Qualitative data | Data collected through qualitative research methods, including surveys, focus groups, and interviews. |

**Table 5. Overview of health equity assessment domains, active stakeholders, data sources, and key outcomes across 8 key decision points.** Data sources and key outcomes written in red are specific to evaluating an existing AI solution. Ones written in blue are specific to evaluating a new AI solution.

| Adoption stage | Decision point | Assessment domains | Active stakeholders | Data sources | Key outcomes |
|---|---|---|---|---|---|
| Problem identification and procurement | 1. Identify and prioritize a problem | Fitness for purpose | Strategic<br>Operational<br>Clinical<br>Patient | • Literature review<br>• Qualitative data | • Equitably prioritized problem<br>• Preliminary assessment of health inequities<br>• A preliminary list of disadvantaged patient subgroups |
| | 2. Define AI product scope and intended use | Fairness<br>Reliability and validity | Strategic<br>Operational<br>Clinical<br>Technical<br>Patient<br>Regulatory | • Local healthcare retrospective data<br>• Local non-healthcare data<br>• Training data | • A list of alternative solutions<br>• Ideal label for model development<br>• Regulatory approval to access and use local healthcare data<br>• Assessment of health inequities in the local healthcare retrospective data<br>• A list of disadvantaged patient subgroups<br>• Flag for representation bias in local healthcare retrospective data<br>• Assessment of health inequities in the training data<br>• Flag for representation bias in the training data<br>• Flag for label choice bias in the training data<br>• Flag for measurement bias in the training data<br>• Flag for hidden stratification in |

| | | | | | |
|---|---|---|---|---|---|
| | | | | | the training data<br>• Assessment of model performance between disadvantaged and advantaged patient subgroups using the training data<br>• Decision to include or exclude SDOH and demographic data in the model<br>• Selection of an AI solution |
| Development and adaptation | 3. Develop success measures | Fairness | Strategic<br>Operational<br>Clinical | • Organizational data<br>• Literature review | • Equity objectives<br>• Fairness metrics |
| | 4. Design AI solution workflow | Fitness for purpose<br>Transparency | Strategic<br>Operational<br>Clinical<br>Regulatory<br>Patient | • Qualitative data | • Recommendations for the solution design gathered from members of disadvantaged patient subgroups<br>• Needs and concerns for the solution design gathered from clinical end-users<br>• Non-technical solution components<br>• Education and training material for clinical end-users<br>• Stakeholder alignment in equity objectives |
| | 5. Generate evidence of safety, efficacy, and equity | Accountability<br>Fairness<br>Reliability and validity | Clinical<br>Technical<br>Patient<br>Operational | • Local healthcare retrospective data<br>• Local healthcare prospective data<br>• Qualitative data | • Assessment of completeness of local healthcare retrospective data<br>• Regulatory approval to access and use local healthcare prospective data<br>• Validation of model performance |

| | | | | | |
|---|---|---|---|---|---|
| | | | | | across disadvantaged patient subgroups in training and local healthcare prospective data<br>• Model performance that aligns with equity objectives<br>• Validation of the AI solution against equity objectives through a prospective pilot study<br><br>• Flag for label choice bias in the training data<br>• Flag for measurement bias in the training data<br>• Flag for hidden stratification in the training data<br>• Assessment of model performance between disadvantaged and advantaged patient subgroups using the training data<br>• Decision to include or exclude SDOH and demographic data in the model |
| Clinical integration | 6. Execute AI solution rollout | Accountability<br>Fairness<br>Transparency | Operational<br>Clinical<br>Technical<br>Patient<br>Regulatory | • Qualitative data | • Communication plan and material for clinical end-users, members of disadvantaged patient subgroups, and others affected by the AI solution<br>• Regulatory approval to implement the AI solution<br>• Post-rollout feedback from clinical end-users and members of disadvantaged and advantaged patient subgroups |

| | | | | | |
|---|---|---|---|---|---|
| Lifecycle management | 7. Monitor the AI solution | Fairness<br>Reliability and validity<br>Transparency | Operational<br>Technical<br>Patient | • Local healthcare prospective data<br>• Qualitative data | • Monitoring outcomes of the model performance<br>• Monitoring outcomes of the work environment<br>• Monitoring outcomes of health inequities across disadvantaged and advantaged patient subgroups |
| | 8. Update or decommission the AI solution | Accountability<br>Fairness<br>Reliability and validity<br>Transparency | Clinical<br>Technical<br>Operational<br>Patient | • Local healthcare retrospective data<br>• Local healthcare prospective data | • Decision on whether updating the AI solution is necessary<br>• Decision on whether decommissioning the AI solution is necessary<br>• Decision on whether expanding the AI solution to the new implementation context is appropriate |

## Decoupling algorithmic fairness from health equity

HEAAL includes procedures that focus on components of the AI model, including training data and outcome labels, and components of the implementation context, including personnel availability and resources for lifecycle management. Procedures that focus on algorithmic fairness are distinct from those that focus on potential impact on health equity. This allows for scenarios that may initially seem unintuitive, in which algorithmic fairness and health equity do not align. For example, consider the scenarios in Table 6.

**Table 6. Four scenarios of alignment between algorithmic fairness and health equity.**

| | AI solution advances health equity | AI solution fails to advance health equity |
|---|---|---|
| AI solution addresses all algorithmic fairness concerns on historical data | Scenario A | Scenario B |
| AI solution fails to address algorithmic fairness concerns on historical data | Scenario C | Scenario D |

Scenarios A and D are consistent with the dominant narrative that closely couples algorithmic fairness and impacts on health equity. In scenario A, an AI solution performs well on a disadvantaged subgroup and once integrated into clinical care enables progress towards an equity objective to improve outcomes for that disadvantaged subgroup. Conversely, in scenario D, an AI solution performs poorly on a disadvantaged subgroup and once integrated into clinical care further widens a health inequity for that disadvantaged subgroup.

Awareness of scenario B is increasing. In one published case study, an AI product built to identify patients at high risk of missing appointments was assessed for use in patient scheduling. A workflow to use the algorithm to double-book patients at high risk of no-shows was determined to worsen health inequities [39]. In other scenarios, an AI product with strong

performance across both disadvantaged and advantaged subgroups may be integrated into a healthcare delivery organization in which resources and personnel are unequally distributed. Under-resourced settings that care for disadvantaged subgroups may not be able to allocate the same level of personnel effort as higher-resourced settings to follow up on AI model outputs. Prospective implementation of the AI solution could maintain or worsen health inequities.

Lastly, scenario C goes against the dominant narrative of AI. The framework development process surfaced at least two categories of use cases in scenario C. In both categories, there is an inequity in the workup or diagnosis of a medical condition targeted by the AI solution. In the first category, which we call “inequitable underdiagnosis,” the medical condition is evenly distributed across advantaged and disadvantaged subgroups. Due to inequities in workup or diagnosis, the medical condition is underdiagnosed in disadvantaged subgroups. Example use cases within this category include AI products that target peripheral artery disease (PAD), chronic kidney disease (CKD), and mental illness. An AI solution may appear to perform poorly on historical data for a disadvantaged subgroup compared to an advantaged subgroup. However, estimates of model performance on historical data are inaccurate because a substantial portion of positive cases (e.g., patients with PAD, CKD, or mental illness) in the disadvantaged subgroup are undiagnosed. Prospective implementation of the AI solution with proactive outreach to conduct appropriate workup and diagnosis for all high-risk patients will be required to assess the impact on health equity.

In the second Scenario C category, which we call “inequitable overdiagnosis,” the medical condition is unevenly distributed across advantaged and disadvantaged subgroups. Due to inequities in workup or diagnosis, the medical condition is over-diagnosed in disadvantaged subgroups. Example use cases within this category include behavioral emergencies in the inpatient setting that can prompt the use of physical or chemical restraints, child abuse or neglect that can prompt family separation, and organ transplant ineligibility. An AI solution may appear to perform poorly (or better) on historical data for a disadvantaged

subgroup compared to an advantaged subgroup. However, systemic racism may be entangled in the diagnosis process and the equity objective can be to reduce event rates across both disadvantaged and advantaged subgroups. Prospective implementation of the AI solution with proactive outreach to provide medical and social support for all high-risk patients can improve health equity.

# Discussion

Healthcare delivery organizations are grappling with how to ensure that AI does not worsen health inequities. To mitigate the risk of AI worsening health inequities, a community of clinical, technical, and operational leaders within healthcare delivery organizations convened to strengthen internal AI governance programs. Through developing and testing the HEAAL framework, we provide healthcare delivery organizations with actionable guidance on how to approach this challenge. Below, we describe how the HEAAL framework is differentiated from prior work and makes a unique contribution to the field.

## Community-generated framework

HEAAL is a community-generated framework. Stakeholders across healthcare delivery organizations and relevant domains of expertise, including community engagement, were actively engaged and their concerns were systematically captured through a rigorous co-design process. We used a case-based workshop method to ground the initial discovery activities. This approach helped us create a comprehensive framework for equity assessment by gaining broad input from a diverse community of practitioners. An important advantage of this method is that it can promote honest discussions of bold and diverse ideas on a sensitive subject while establishing trust and safety among those involved.

Another strength of this method is its use of real-world examples. The use of real-world examples made it easier for participants to relate to the work presented and unpack complex concepts. As a result, all discussions and recommendations for HEAAL are grounded in the experiences of practitioners who implement and evaluate similar solutions in their institutions.

## Comprehensive and usable framework

HEAAL procedures are designed to be comprehensive. It contains a comprehensive set of procedures that are tailored to new and existing AI solutions and span all stages of the AI adoption lifecycle. Comprehensive procedures mitigate ambiguity when evaluating the impact of a new AI solution on health equity across the entire lifecycle of an AI solution. Mutually exclusive procedures ensure that there is no redundancy across procedures and that no single procedure outweighs others.

By conducting multiple rounds of usability testing that applied the framework to a real use case, we ensured that the procedures were clearly written and usable in practice. Every procedure contains step-by-step guidance to support users.

## Implications for practice

The HEAAL framework highlights four complex challenges that will require significant attention and investment by diverse stakeholders. First, the framework exposes an *Achilles heel* of AI by emphasizing the role of context-specific factors in health equity assessments. AI solutions are portrayed as highly scalable and able to rapidly deliver value to healthcare organizations. This perception has gained significant momentum since the emergence of Large Language Models (LLMs). However, the HEAAL framework is applied in a context-specific fashion that is not easily scalable. An AI solution that is evaluated by one setting through HEAAL should be reassessed when a different setting considers implementation. Even if the

same technology is being used, when the setting changes, the use case involves a different patient population, different stakeholders, different sources of data, and different clinical workflow. To ensure health equity, HEAAL should be applied every time a healthcare organization considers using an AI solution.

Second, successful implementation of HEAAL requires significant expertise, technology infrastructure to gather diverse robust datasets, and personnel effort. Despite the framework being publicly accessible and consensus among healthcare leaders to eliminate bias in AI, healthcare delivery organizations will not be able to apply the entire framework to every AI solution without significant support. HEAAL emphasizes the importance of collaborative governance models for medical AI, in which centralized authorities (e.g., FDA, CMS) coordinate and support local governance activities [40]. Significant infrastructure and technical assistance investments must be made to support low-resource settings to adopt HEAAL.

Third, applying a tool like HEAAL must be accounted for in reimbursement for medical AI. An AI procurement and implementation process that uses HEAAL will necessitate significantly higher investment than a process that skips the assessment of health equity impacts. Without financial incentives to support the adoption of HEAAL, healthcare delivery organizations seeking to minimize discrimination due to AI will avoid AI products altogether, even if an AI solution could improve quality, safety, and equity. One potential financial incentive is to reimburse products that advance equity objectives through a rigorous HEAAL assessment at a higher rate than products lacking such evidence.

Fourth, there is concern that HEAAL can serve as a ‘rubber stamp’ for healthcare organizations to outwardly project commitment to equity while minimizing changes to organizational practices. For example, an organization could cherry-pick a patient population or the results of analyses to minimize the projected impact of an AI model on health inequities. To address this, there is an opportunity for independent registries that provide transparency and traceability throughout HEAAL procedures to hold healthcare organizations accountable. Similar

to the registration of clinical trials, healthcare organizations can register AI product assessments and report progress in conducting HEAAL procedures. Organizations that report outputs that deviate from the initial intended scope of AI product use will face strict scrutiny from internal and external stakeholders.

## Limitations and future directions

While the HEAAL framework is valid, thorough, and user-friendly, it has several limitations. First, the current framework is developed based on the US context. Users seeking to address equity concerns in other countries may find gaps in the framework or procedures that seem less relevant.

Second, the framework was designed and tested using AI products developed in-house. The pediatric sepsis model was built within Duke Health and the two case studies presented at the workshop were also built within Parkland Health and NewYork-Presbyterian. To further validate the framework for a broader set of use cases, HEAAL will need to be applied to scenarios where healthcare organizations procure pre-existing AI solutions that are developed externally, which represents the overwhelming proportion of AI implemented in healthcare.

Third, HEAAL has not been validated yet for a generative AI use case. By making HEAAL publicly available for organizations to test on their own algorithms, we hope to continue iterating on the framework and adapting it for additional use cases.

The HEAAL framework is meant to be continuously improved and adapted. HAIP acknowledges the dynamic nature of AI technologies and the evolving landscape of health disparities. We hope that HEAAL effectively mitigates health disparities in AI-driven healthcare and addresses evolving challenges and opportunities. We are committed to staying at the forefront of equitable healthcare delivery and gathering ongoing feedback from practitioners to ensure that the framework stays responsive to emerging health equity issues. This collaborative

approach calls on stakeholders to test the framework in practice, provide feedback on its usability, exchange knowledge, and share real-world applications in diverse healthcare settings.

# Acknowledgements

We thank the Gordon and Betty Moore Foundation for supporting the project. We thank David Robinson for sharing his insights as a framework developer. We thank Deirdre Mulligan for her support as a Health AI Partnership leader prior to her leave in January 2023. We thank Willie Boag and Shems Saleh for testing a prototype of the framework and providing feedback to improve the clarity and usability of the procedures, especially with a technical focus. We thank Duke Heart Center for helping administer and manage the grant.

# References

1. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nature medicine. 2019 Jan;25(1):30-6.
2. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. New England Journal of Medicine. 2019 Apr 4;380(14):1347-58.
3. Sendak MP, D'Arcy J, Kashyap S, Gao M, Nichols M, Corey K, Ratliff W, Balu S. A path for translation of machine learning products into healthcare delivery. EMJ Innov. 2020 Jan 27;10:19-00172.
4. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019 Jan;25(1):44-56.
5. Adams R, Henry KE, Sridharan A, Soleimani H, Zhan A, Rawat N, Johnson L, Hager DN, Cosgrove SE, Markowski A, Klein EY. Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis. Nature medicine. 2022 Jul;28(7):1455-60.
6. Escobar GJ, Liu VX, Schuler A, Lawson B, Greene JD, Kipnis P. Automated identification of adults at risk for in-hospital clinical deterioration. New England Journal of Medicine. 2020 Nov 12;383(20):1951-60.
7. He B, Kwan AC, Cho JH, Yuan N, Pollick C, Shiota T, Ebinger J, Bello NA, Wei J, Josan K, Duffy G. Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature. 2023 Apr 20;616(7957):520-4.
8. United States Government Accountability Office Report to Congressional Requesters Artificial Intelligence in Health Care Benefits and Challenges of Machine Learning Technologies for Medical Diagnostics With content from the National Academy of Medicine [Internet]. 2022. Available from: https://www.gao.gov/assets/gao-22-104629.pdf

9. Raji ID, Smart A, White RN, Mitchell M, Gebru T, Hutchinson B, Smith-Loud J, Theron D, Barnes P. Closing the AI accountability gap: Defining an end-to-end framework for internal algorithmic auditing. InProceedings of the 2020 conference on fairness, accountability, and transparency 2020 Jan 27 (pp. 33-44).
10. Wu E, Wu K, Daneshjou R, Ouyang D, Ho DE, Zou J. How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals. Nature Medicine. 2021 Apr;27(4):582-4
11. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019 Oct 25;366(6464):447-53.
12. Pierson E, Cutler DM, Leskovec J, Mullainathan S, Obermeyer Z. An algorithmic approach to reducing unexplained pain disparities in underserved populations. Nature Medicine. 2021 Jan;27(1):136-40.
13. Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, Gao G. Addressing algorithmic bias and the perpetuation of health inequities: An AI bias aware framework. Health Policy and Technology. 2023 Mar 1;12(1):100702.
14. The White House. Blueprint for an AI Bill of Rights [Internet]. The White House. 2022. Available from: https://www.whitehouse.gov/ostp/ai-bill-of-rights/
15. Rights (OCR) O for C. HHS Announces Proposed Rule to Strengthen Nondiscrimination in Health Care [Internet]. HHS.gov. 2022. Available from: https://www.hhs.gov/about/news/2022/07/25/hhs-announces-proposed-rule-to-strengthen-nondiscrimination-in-health-care.html
16. Federal Register :: Request Access [Internet]. unblock.federalregister.gov. Available from: https://www.federalregister.gov/documents/2023/04/18/2023-07229/health-data-technology-and-interoperability-certification-program-updates-algorithm-transparency-and
17. Attorney General Bonta Launches Inquiry into Racial and Ethnic Bias in Healthcare Algorithms [Internet]. State of California - Department of Justice - Office of the Attorney General. 2022. Available from: https://oag.ca.gov/news/press-releases/attorney-general-bonta-launches-inquiry-racial-and-ethnic-bias-healthcare
18. Celi LA, Cellini J, Charpignon ML, Dee EC, Dernoncourt F, Eber R, Mitchell WG, Moukheiber L, Schirmer J, Situ J, Paguio J. Sources of bias in artificial intelligence that perpetuate healthcare disparities—A global review. PLOS Digital Health. 2022 Mar 31;1(3):e0000022.
19. Daneshjou R, Smith MP, Sun MD, Rotemberg V, Zou J. Lack of transparency and potential bias in artificial intelligence data sets and algorithms: a scoping review. JAMA dermatology. 2021 Nov 1;157(11):1362-9.
20. Kaushal A, Altman R, Langlotz C. Geographic distribution of US cohorts used to train deep learning algorithms. Jama. 2020 Sep 22;324(12):1212-3.
21. Naudé W. Artificial intelligence vs COVID-19: limitations, constraints and pitfalls. AI & society. 2020 Sep;35(3):761-5.
22. Wang L, Zhou Y, He J, Zhu B, Wang F, Tang L, Kleinsasser M, Barker D, Eisenberg MC, Song PX. An epidemiological forecast model and software assessing interventions on the COVID-19 epidemic in China. Journal of Data Science. 2020 Jul 1;18(3):409-32.

23. Bhavani, S. V., Wiley, Z., Verhoef, P. A., Coopersmith, C. M., & Ofotokun, I. (2022). Racial differences in detection of fever using temporal vs oral temperature measurements in hospitalized patients. *Jama*, *328*(9), 885-886.
24. Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial bias in pulse oximetry measurement. New England Journal of Medicine. 2020 Dec 17;383(25):2477-8.
25. Adam H, Yang MY, Cato K, Baldini I, Senteio C, Celi LA, Zeng J, Singh M, Ghassemi M. Write it like you see it: Detectable differences in clinical notes by race lead to differential model recommendations. InProceedings of the 2022 AAAI/ACM Conference on AI, Ethics, and Society 2022 Jul 26 (pp. 7-21).
26. Sun M, Oliwa T, Peek ME, Tung EL. Negative Patient Descriptors: Documenting Racial Bias In The Electronic Health Record: Study examines racial bias in the patient descriptors used in the electronic health record. Health Affairs. 2022 Feb 1;41(2):203-11.
27. Badgeley MA, Zech JR, Oakden-Rayner L, Glicksberg BS, Liu M, Gale W, McConnell MV, Percha B, Snyder TM, Dudley JT. Deep learning predicts hip fracture using confounding patient and healthcare variables. NPJ digital medicine. 2019 Apr 30;2(1):31.
28. Zech JR, Badgeley MA, Liu M, Costa AB, Titano JJ, Oermann EK. Confounding variables can degrade generalization performance of radiological deep learning models. arXiv preprint arXiv:1807.00431. 2018 Jul 2.
29. Huang J, Galal G, Etemadi M, Vaidyanathan M. Evaluation and mitigation of racial bias in clinical machine learning models: scoping review. JMIR Medical Informatics. 2022 May 31;10(5):e36388.
30. Mccradden M, Odusi O, Joshi S, Akrout I, Ndlovu K, Glocker B, Maicas G, Liu X, Mazwi M, Garnett T, Oakden-Rayner L. What's fair is… fair? Presenting JustEFAB, an ethical framework for operationalizing medical ethics and social justice in the integration of clinical machine learning: JustEFAB. InProceedings of the 2023 ACM Conference on Fairness, Accountability, and Transparency 2023 Jun 12 (pp. 1505-1519).
31. Nazer LH, Zatarah R, Waldrip S, Ke JX, Moukheiber M, Khanna AK, Hicklen RS, Moukheiber L, Moukheiber D, Ma H, Mathur P. Bias in artificial intelligence algorithms and recommendations for mitigation. PLOS Digital Health. 2023 Jun 22;2(6):e0000278.
32. Suresh H, Guttag J. A framework for understanding sources of harm throughout the machine learning life cycle. InEquity and access in algorithms, mechanisms, and optimization 2021 Oct 5 (pp. 1-9).
33. Wang HE, Landers M, Adams R, Subbaswamy A, Kharrazi H, Gaskin DJ, Saria S. A bias evaluation checklist for predictive models and its pilot application for 30-day hospital readmission models. Journal of the American Medical Informatics Association. 2022 Aug 1;29(8):1323-33.
34. Kim JY, Boag W, Gulamali F, Hasan A, Hogg HD, Lifson M, Mulligan D, Patel M, Raji ID, Sehgal A, Shaw K. Organizational Governance of Emerging Technologies: AI Adoption in Healthcare. InProceedings of the 2023 ACM Conference on Fairness, Accountability, and Transparency 2023 Jun 12 (pp. 1396-1417).
35. Sendak M, Kim JY, Hasan A, et al. Empowering U.S. healthcare delivery organizations: Cultivating a community of practice to harness AI and advance health equity. PLOS Digital Health. Forthcoming 2023.

36. 1.PILLAR: HEALTH EQUITY [Internet]. 2022. Available from: https://www.cms.gov/files/document/health-equity-fact-sheet.pdf
37. Tamer YT, Karam A, Roderick T, Miff S. Know Thy Patient: A Novel Approach and Method for Patient Segmentation and Clustering Using Machine Learning to Develop Holistic, Patient-Centered Programs and Treatment Plans. NEJM Catalyst Innovations in Care Delivery. 2022 Aug 23;3(4).
38. Zhang Y, Wang S, Hermann A, Joly R, Pathak J. Development and validation of a machine learning algorithm for predicting the risk of postpartum depression among pregnant women. Journal of affective disorders. 2021 Jan 15;279:1-8.
39. Murray SG, Wachter RM, Cucina RJ. Discrimination by artificial intelligence in a commercial electronic health record—a case study. Health Affairs Forefront. 2020.
40. Price WN, Sendak M, Balu S, Singh K. Enabling collaborative governance of medical AI. Nature Machine Intelligence. 2023 Aug 9:1-3.